RecruitingPhase 1

Dopamine and Sensorimotor Function in Stuttering

United States40 participantsStarted 2025-09-30

Plain-language summary

This study is being done to understand the effect of aripiprazole on adults who stutter. Stuttering is a disorder that affects speech fluency. This study aims to understand sensorimotor pathways of stuttering and possible interventions.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * native speakers of American English * for adults who stutter, presence of stuttering will be confirmed, with onset before age 6 years * Normal hearing * Ages of 18 to 65 years * healthy adults without hearing-language difficulties Exclusion Criteria: * self-reported speech-language-hearing difficulties other than stuttering * self-reported neurological or psychological problems * other medications (drugs that affect dopaminergic system and/or benzodiazepines)

What they're measuring

Pre-speech auditory modulation

Timeframe: 3-4 hours after intervention dose is delivered

Speaking Induced Suppression (SIS)

Timeframe: 3-4 hours after intervention

Centering

Timeframe: 3-4 hours after intervention

Feedback alterations

Timeframe: 3-4 hours after intervention

Trial details

NCT IDNCT07215884

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-30

Contact for this trial

Natalie Brunwin, MS

4154766888 snl-bil@ucsf.edu

View on ClinicalTrials.gov More Stuttering, Adult trials